Overview

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Recruiting

Trial end date:
2024-03-11

Target enrollment:

Participant gender:

Summary

The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).

Phase:

Phase 2

Details

Lead Sponsor:

Cardiff Oncology

Treatments:

Fluorouracil
Irinotecan
Leucovorin
Onvansertib